We studied the interaction between rifampin and fusidic acid against a group of staphylococci. Of the 20 coagulase-positive strains studied, checkerboard studies revealed synergy in 3 and indifference in 17; time-kml studies revealed synergy in 18 of 19 coagulase-positive strains at both 24 and 48 h. Of the 19 coagulase-negative strains, checkerboard studies revealed synergy in 6 and indifference in 13; time-kill studies revealed synergy in 6 of 18 coagulase-negative strains at 24 h and in 17 of 18 coagulase-negative strains at 48 h. The combination of rifampin and fusidic acid warrants further evaluation in the therapy of staphylococcal disease.
Methicillin resistance among Staphylococcus aureus and S. epidermidis has become endemic in many areas of the United States and Europe (4) . Vancomycin remains the primary drug used to treat these infections, but its use involves several drawbacks. It must be given intravenously, and it is not tolerated by some patients (2) .
Rifampin and fusidic acid are both highly active against staphylococci, but resistance develops rapidly when either agent is used alone (7) . For this reason, we sought to study the interaction between rifampin and fusidic acid against a group of coagulase-positive and -negative staphylococci.
A total of 20 strains of methicillin-resistant S. aureus were used in these studies. MICs were determined, and checkerboard studies were performed by a microtiter assay in unsupplemented MuellerHinton broth. The method of Krogstad and Moellering was used (5). The final volume of each well was 100 R1l. The inoculum was prepared by serial dilution of an overnight culture into Mueller-Hinton broth and was checked by serial dilution in saline, with subsequent plating of 25 ,ul onto Mueller-Hinton agar. Microtiter and agar plates were incubated for 18 h at 37°C. The final inhibitory concentration (FIC) was calculated with a standard formula (5). Synergy was defined as an FIC <0.5, and antagonism was defined as an FIC >2.
Antibiotic combinations were tested in Mueller-Hinton broth by a time-kill method previously described (6). Synergism was defined as a decrease of .2 log10 CFU/ml produced by the combination compared with either agent alone or both agents in combination. Antagonism was defined as an increase of 2 log10 CFU/ml, the combination being compared with each agent alone. Samples were removed for colony counts at 4, 24, and 48 h, and, after serial dilution in saline, were plated onto Mueller-Hinton agar. They were incubated for 24 h at 35°C and inspected for growth. The combination concentrations were as follows: fusidic acid, 0.5 ,ug/ml; and rifampin, 5 ,ug/ml.
All strains of S. aureus were susceptible to rifampin and fusidic acid. The MICs of rifampin for 50 and 90% of the strains tested were 0.004 and 0.006 ,ug/ml, respectively. The range was 0.007 to 0.017 jig/ml. The MICs of fusidic acid for Table 1 ). The one strain that did not demonstrate synergy was completely killed by both the combination and the fusidic acid alone. Rifampin and fusidic acid usually produced inhibition at 4 h, but regrowth of resistant organisms was evident at 24 or 48 h in all strains. In no strain did resistance occur when the combination was used. A cumulative (mean) time-kill curve for the studies is shown in Fig. 1 .
Of the 19 coagulase-negative strains studied by the checkerboard technique, 6 demonstrated synergy and 13 demonstrated indifference to the combination. Of the 18 strains studied by time-kill curves, 17 demonstrated synergy at 48 h, but only 6 of the 18 demonstrated synergy at 24 h. Antagonism was not seen in any of the strains. Rifampin-and fusidic acid-resistant strains did not emerge in any of the experiments. A mean time-kill curve for the studies is shown in Fig. 1 The combination of fusidic acid and rifampin against coagulase-negative strains produced somewhat different results. The checkerboard and 24-h time-kill curves suggested synergy in 6 of 19 and 6 of 18 strains, respectively. However, by 48 h synergy was seen in 17 of 18 strains examined by the time-kill method. In addition, the magnitude of the effect was much greater against coagulase-positive strains.
The results of these studies suggest that the combination of fusidic acid and rifampin warrants further evaluation in the therapy of both coagulase-negative and -positive staphylococcal infections.
